Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Phio Pharmaceuticals Corp. Common Stock

PHIO

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Last trade $0.7374
Day change -$0.0148 (-1.97%)
Day range $0.691 – $0.771
Volume 59,526
Market cap $9M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$8.96M
Price / earnings
—
Price / book
1.04×
Price / sales
—
EV / sales
—
EV / EBITDA
0.11×

Profitability

Earnings per share
-$1.23
Return on assets
-129.65%
Return on equity
-170.21%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
4.19×
Quick ratio
4.19×
Cash ratio
3.93×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.4M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PHIO, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$1.21M$1.19M$1.37M$1.06M$1.32M$1.24M$986K$689K
Research and development$3.06M$3.08M$2.79M$1.48M$1.18M$1.07M$886K$985K
Total operating expenses$4.27M$4.27M$4.17M$2.53M$2.51M$2.31M$1.87M$1.67M
Operating income-$4.27M-$4.27M-$4.17M-$2.53M-$2.51M-$2.31M-$1.87M-$1.67M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$4.16M-$4.14M-$4M-$2.37M-$2.39M-$2.17M-$1.77M-$1.63M
Income taxes$0$0$0$0$0$0$0$0
Net income-$4.16M-$4.14M-$4M-$2.37M-$2.39M-$2.17M-$1.77M-$1.63M
Net income attributable to common shareholders-$4.16M-$4.14M-$4M-$2.37M-$2.39M-$2.17M-$1.77M-$1.63M
EBITDA-$4.27M-$4.27M-$4.17M-$2.53M-$2.5M-$2.31M-$1.87M-$1.67M
Basic earnings per share-$0.36-$0.36-$0.34-$0.25-$0.44-$0.45-$0.41—
Diluted earnings per share-$0.36-$0.36-$0.34-$0.25-$0.44-$0.45-$0.41—

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Phio Posts Wider Loss in Fiscal Q2

Phio Pharmaceuticals reported a Q2 2025 net loss of $2.2 million, with its lead candidate PH-762 showing promising early clinical results in cancer therapy. The company's INTASYL platform demonstrated positive safety and efficacy signals in gene-silencing cancer treatments.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jul 5, 20241-for-9reverse split
Jan 26, 20231-for-12reverse split
Jan 15, 20201-for-55reverse split
Jan 8, 20181-for-10reverse split
Apr 18, 20161-for-10reverse split